DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])

Inclusion Criteria: * Histopathologically or cytologically proven adenocarcinoma of the prostate * Documented metastatic prostate adenocarcinoma * Documented progression while on androgen ablation therapy detected by rising prostate specific antigen (PSA) and/or imaging * Age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) performance status \<= 2 * Adequate hematologic, renal and hepatic function * Life expectancy \>= 3 months Exclusion Criteria: * Prior chemotherapy, except estramustine * Prior chemotherapy with docetaxel * Prior isotope therapy (e.g., strontium-89, samarium-153, etc.) * One or more contraindications to the use of corticosteroids * History of cancer-related hypercalcemia